行情

BPTH

BPTH

Bio-Path控股
NASDAQ

实时行情|Nasdaq Last Sale

4.900
+0.280
+6.06%
盘后: 4.760 -0.14 -2.86% 19:43 04/03 EDT
开盘
4.620
昨收
4.620
最高
4.930
最低
4.590
成交量
7.52万
成交额
--
52周最高
24.73
52周最低
2.920
市值
1,809.01万
市盈率(TTM)
-1.4932
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BPTH价格均价为25.00,最高价位25.00,最低价为25.00。

EPS

BPTH 新闻

更多
  • GRPN, TOPS, NCLH and BGCP among midday movers
  • Seeking Alpha - Article · 03/27 16:41
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Edited Transcript of BPTH earnings conference call or presentation 6-Mar-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 03/13 20:59
  • Bio-Path Holdings Appoints Ernst & Young as New Auditor
  • GlobeNewswire · 03/11 11:00

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

BPTH 简况

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
展开

微牛提供Bio-Path Holdings Inc(NASDAQ-BPTH)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BPTH股票新闻,以帮助您做出投资决策。